Overview

This trial is active, not recruiting.

Condition ischemic stroke
Phase phase 4
Sponsor Siu Po Sit
Start date September 2010
End date December 2016
Trial size 150 participants
Trial identifier NCT01193569, CLP2818

Summary

The objective of this study is to determine the natural history of acute ischemic stroke from large vessel thromboembolism in the brain. The target population is a stroke cohort with a known infarct volume who presents within 8 hours from symptom onset with a NIH Stroke Scale (NIHSS) score >10 who are eligible for mechanical thrombectomy but without receiving the treatment. Functional outcome as defined by the modified Rankin Scale (mRS) of all enrolled patients will be followed for 90 days after the index event.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective
Arm
Standard of Care for stroke except mechanical therapy

Primary Outcomes

Measure
Proportion of patients with a modified Rankin score of 2 or less
time frame: 90 days after the procedure

Secondary Outcomes

Measure
NIHSS score of 0-1 or a 10 or more points improvement
time frame: Discharge
All cause mortality
time frame: 90 days post-procedure
Incidents of symptomatic and asymptomatic intracranial hemorrhage
time frame: 90 days post-procedure

Eligibility Criteria

Male or female participants from 18 years up to 85 years old.

Inclusion Criteria: - From 18 to 85 years of age - Evidence of proximal anterior circulation large vessel occlusion (TIMI 0-1/TICI 0-1)from CT Angiography. Target vessel occlusion may include the supra-clinoid segment of the ICA through the M1 segment of the MCA. - Presented with symptoms consistent with acute ischemic stroke within 8 hours of symptom onset. Patients who presented within 3 hours must be ineligible or refractory to IV rtPA therapy. - At time of enrollment, neurological deficit resulting in an NIH Stroke Scale (NIHSS) score > 10 - Known core infarct volume assessed by CTP, CTA or DWI scans Exclusion Criteria: - History of stroke in the past 3 months. - Pre-existing neurological or psychiatric disease that could confound the study results such as a pre-stroke mRS score >1 - Known severe allergy to contrast media - Uncontrolled hypertension (defined as systolic blood pressure >185 mmHg or diastolic blood pressure >110 mmHg) - CT evidence of the following conditions before enrollment: - Significant mass effect with midline shift - Evidence of intracranial hemorrhage - Treated with endovascular therapy for acute stroke - Life expectancy was thought to be less than 90 days prior to stroke due to non-stroke illness - Participation in another clinical investigation that could confound the evaluation of the study

Additional Information

Official title The SOS Study: A Study of Survival and Outcome After Stroke
Principal investigator Iris Q Grunwald, MD
Description The objective of this observational study is to determine the natural history of acute ischemic stroke from large vessel thromboembolism in the brain. The target population is a stroke cohort with a known infarct volume who presents within 8 hours from symptom onset with a NIH Stroke Scale (NIHSS) score >10. Functional outcome as defined by the modified Rankin Scale (mRS) of all enrolled patients will be followed for 90 days after the index event. This is a prospective, single arm, multi-center trial. Up to 200 patients at up to 30 centers will be enrolled in the study. It is anticipated that up to 150 evaluable patients will be needed for analysis. The sample size estimate is based on the primary study functional outcome at 90 days as defined by a mRS of 0-2. Assuming that this observational study will have as outcome of 25% (37/150) mRS 0-2 at day 90, the expected two-sided exact binomial confidence interval is (18%, 32%). This sample size is adequate to estimate the mRS outcome of 0-2 at day 90 for the natural history of acute ischemic stroke.
Trial information was received from ClinicalTrials.gov and was last updated in March 2016.
Information provided to ClinicalTrials.gov by Penumbra Inc..